SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Crucell N.V. (CRXL)
An SI Board Since November 2000
Posts SubjectMarks Bans Symbol
560 26 0 CRXL
Emcee:  Jongmans Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
510Crucell Announces STAR(R) Research and Commercial License Agreement with Centocoscaram(o)uche-1/6/2009
509DSM Biologics and Crucell Announce PER.C6(R) Research License Agreement with Glascaram(o)uche-12/18/2008
508Crucell signs second exclusive license agreement with Talecris Biotherapeutics; LJM-12/17/2008
507Crucell Advances Hepatitis Vaccine in China The Dutch biopharma Crucell N.V. (CA.J. Mullen-12/11/2008
506Crucell's press release on the same study: Crucell Announces Excellent ResuA.J. Mullen-12/11/2008
505Crucell antibody beats Tamiflu in preclinical test LONDON, Dec 11 (Reuters) - Annigel bates-12/11/2008
504Probably, but not <i>necessarily</i>; it could be a proprietary compDewDiligence_on_SI-11/25/2008
503Looks like Gedeon Richter Plc. is thinking biogenerics: "Crucell N.V. (Euridos-11/25/2008
502>>Don't misunderstand me<< Don't worry, I'm cured of thnigel bates-11/11/2008
501No, but the abstract reads exactly like what I expected. Don't misunderstanscaram(o)uche-11/11/2008
500This was good for 10% in Europe this morning... <i>Outlook 2008: Crucellnigel bates-11/11/2008
499Leiden, The Netherlands (November 11, 2008) - Dutch biopharma company Crucell N.nigel bates-11/11/2008
498Did you look at the paper? (Jacobsen is the Avidex guy - bought by Medigene, andnigel bates-11/10/2008
497OT: "engineered assassin cells"..... sounds like they're meanescaram(o)uche-11/10/2008
496Tangential interest, but this seems the best place to post: Souped-up immune cenigel bates-11/10/2008
495Aeras and Crucell Announce TB Vaccine Clinical Trial in Kenya; Promising VaccineA.J. Mullen-10/17/2008
494Lonza and Crucell enter into long term agreement Thursday September 25, 1:35 am A.J. Mullen-9/25/2008
493New contracts awarded for Quinvaxem(R) and Hepavax-Gene(R) Tuesday September 23,nigel bates-9/23/2008
492Crucell Signs Exclusive License Agreement with Talecris Biotherapeutics Thursdaynigel bates-9/23/2008
491Crucell shares rise on deal to supply cell lines Wednesday June 25, 2:19 pm ET A.J. Mullen-6/25/2008
490Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce EncourLJM-4/9/2008
489Crucell Announces First in Man Study with New Adenovirus Vector Thursday April 3nigel bates-4/3/2008
488US Phase 2 Rabies study starts a little earlier than expected. Interesting tpgo-neil-3/31/2008
487GO Capital Halts Redemptions On EUR600M Hedge Fund Mar 12, 2008 11:33:45 (ET) LJM-3/12/2008
486If the fall was based on a misreading of the patent situation I don't think tom pope-1/16/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News